BNXT — BioNxt Solutions Share Price
0.000.00%
Last trade - 00:00- CA$97.08m
- CA$104.14m
- CA$0.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4,479.96 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -22423.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.35 | 0.29 | 0.3 | 0.37 | 0.03 | n/a | n/a | -33.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- December 12th, 2017
- Public Since
- August 6th, 2019
- No. of Employees
- 15
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 116,964,754
- Address
- Suite 270 - 1820 Fir Street, VANCOUVER, V6J 3B1
- Web
- https://bionxt.com/
- Phone
- +1 7808186422
- Contact
- Hugh Rogers
- Auditors
- Davidson & Company LLP
Upcoming Events for BNXT
BioNxt Solutions Inc Annual Shareholders Meeting
Q3 2025 BioNxt Solutions Inc Earnings Release
Similar to BNXT
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
Asia Green Biotechnology
Canadian Securities Exchange
FAQ
What is the BioNxt Solutions share price?
As of Today at 19:36 UTC, shares in BioNxt Solutions are trading at CA$0.83. This share price information is delayed by 15 minutes.
How has the BioNxt Solutions share price performed this year?
Shares in BioNxt Solutions last closed at CA$0.83 and the price had moved by +219.23% over the past 365 days. In terms of relative price strength the BioNxt Solutions share price has outperformed the Toronto Stock Exchange 300 Composite Index by +163.19% over the past year.
What are the analyst and broker recommendations for BioNxt Solutions?
There is no consensus recommendation for this security.
Find out moreWhat is the BioNxt Solutions dividend yield?
BioNxt Solutions does not currently pay a dividend.
Does BioNxt Solutions pay a dividend?
BioNxt Solutions does not currently pay a dividend.
When does BioNxt Solutions next pay dividends?
BioNxt Solutions does not currently pay a dividend.
How do I buy BioNxt Solutions shares?
To buy shares in BioNxt Solutions you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioNxt Solutions?
As of the previous close price of CA$0.83, shares in BioNxt Solutions had a market capitalisation of CA$97.08m.
Where are BioNxt Solutions shares listed?
Here are the trading details for BioNxt Solutions:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: BNXT
What kind of share is BioNxt Solutions?
Based on an overall assessment of its quality, value and momentum BioNxt Solutions is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioNxt Solutions share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the BioNxt Solutions share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioNxt Solutions. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +48.73%.
As of the last closing price of CA$0.83, shares in BioNxt Solutions were trading +36.46% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioNxt Solutions PE Ratio?
The BioNxt Solutions PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioNxt Solutions?
We do not have data on BioNxt Solutions' directors